Instalab

Peanut (Ara h 2) IgE Test Blood

A blood test that helps distinguish true peanut allergy from harmless sensitization more reliably than standard whole-peanut testing.

Should you take a Peanut (Ara h 2) IgE test?

This test is most useful if any of these apply to you.

Told You Have a Peanut Allergy
If a standard test labeled you allergic, this can help clarify whether it is truly dangerous or harmless sensitization being misread.
Introducing Peanut to a High-Risk Infant
If your baby has severe eczema, other food allergies, or a peanut-allergic sibling, this can help guide pre-introduction decisions.
Doing Peanut Immunotherapy
Track whether your immune system is shifting away from allergy as you progress through oral or sublingual immunotherapy.
Watching Your Child Outgrow Peanut Allergy
Roughly one in three children outgrow peanut allergy by age 10; serial testing reveals the trajectory long before a food challenge.

About Peanut (Ara h 2) IgE

If you or your child has ever reacted to peanut, been told to avoid it based on a positive allergy test, or had a vague sense of peanut sensitivity, this is one of the most useful blood tests to help settle the question. It can help distinguish between a true peanut allergy that could cause a serious reaction and harmless sensitization that often gets mistaken for allergy on standard tests.

The test measures an antibody (called IgE) that your immune system has built specifically against Ara h 2, the main allergy-triggering protein inside a peanut. A clear result here can help confirm an allergy, reduce unnecessary food avoidance, and reduce the need for a supervised oral food challenge, which is the older way of proving peanut allergy.

What This Test Actually Measures

Peanut is not one protein but a mix of several. The protein called Ara h 2 (short for the second allergen identified in Arachis hypogaea, the peanut plant) is the one most strongly tied to real, clinically dangerous peanut allergy. Standard peanut allergy blood tests measure antibodies against the whole peanut, which lumps together harmless and dangerous proteins. This test isolates the antibodies against Ara h 2 alone.

Those antibodies are made by specialized immune cells, many of which sit in the lining of the stomach and gut. When you eat peanut, the antibodies signal mast cells and basophils (immune cells that release allergy chemicals) to release the chemicals that cause hives, swelling, vomiting, breathing trouble, or anaphylaxis. Higher Ara h 2 IgE (immunoglobulin E, the antibody class tied to allergic reactions) generally means more of those antibodies are present and the immune machinery is primed for a reaction.

Why It Beats a Standard Peanut Allergy Test

A standard whole-peanut IgE blood test or skin prick test picks up everyone whose immune system has noticed peanut, including many people who can eat it without trouble. That is the source of many wrongly diagnosed peanut allergies and unnecessary lifelong avoidance. Ara h 2 testing cuts through that noise.

Who Was StudiedWhat Was ComparedWhat They Found
321 high-risk infants who had not yet eaten peanutAra h 2 IgE versus whole-peanut IgE and skin prick testAra h 2 IgE outperformed whole-peanut IgE and skin prick testing for distinguishing true peanut allergy from tolerance
100 UK children evaluated for peanut allergyAra h 2 IgE versus whole-peanut IgEAra h 2 IgE provided higher diagnostic accuracy than whole-peanut IgE for peanut allergy
Korean children evaluated for peanut allergyAra h 2 IgE thresholds for predicting allergyAt a higher Ara h 2 level, every positive result meant true allergy (100% positive predictive value)

Source: Keet et al. 2021 (high-risk infants); Hemmings et al. 2020 (UK children); Kim et al. 2015 (Korean children).

What this means for you: if a basic peanut allergy panel comes back positive but the clinical history is murky, asking specifically for Ara h 2 IgE before committing to lifelong avoidance is worth the extra step. A meta-analysis pooling many of these studies found that antibodies against Ara h 2 are roughly as good as detailed clinical prediction models that combine skin tests, total IgE, and history.

The Peanut Allergy Connection

Higher Ara h 2 IgE tracks with true, food-challenge-confirmed peanut allergy across studies in infants, children, and adults. It is also one of the better blood predictors of more severe reactions and reactions to small amounts of peanut, although it is not perfect at predicting severity on its own.

In a double-blind placebo-controlled study of 102 people, antibody levels against Ara h 2 (along with a related protein called Ara h 6) were the best blood markers for picking out those at risk of moderate-to-severe peanut reactions. Other peanut components like Ara h 1, Ara h 3, Ara h 8, and Ara h 9 generally fail to distinguish true allergy from harmless sensitization.

Tracking Your Trend Over Time

A single Ara h 2 IgE result tells you where you are today. Tracking it over time tells you where you are headed, and that is where the test becomes genuinely valuable for anyone managing or trying to outgrow peanut allergy.

In a longitudinal study of 156 children, falling Ara h 2 IgE levels (often paired with rising peanut-specific IgG, a different antibody type that blocks allergic reactions) were linked to natural resolution of peanut allergy, with about one in three infants outgrowing it by age 10. The same pattern, falling Ara h 2 IgE and rising IgG4, also tracks with successful peanut oral immunotherapy. If you or your child is undergoing oral immunotherapy or watching for natural resolution, the only way to see this shift is repeat testing.

A reasonable cadence: get a baseline test if peanut allergy is suspected or known, repeat in 6 to 12 months if levels are dropping or you are trying immunotherapy, and at least annually if you are watching for resolution in a child.

When Results Can Be Misleading

Ara h 2 IgE is one of the more stable allergy blood markers, but a few things can still cause confusion when interpreting a single value.

  • Low positive values: Levels in the low-positive range overlap between truly allergic and tolerant people. A small elevation does not automatically equal a dangerous allergy and may require an oral food challenge to settle.
  • Assay differences: Different labs use slightly different methods, so absolute values may not be directly comparable between tests run at different facilities. Use the same lab when trending.
  • Population variation: The numeric cutoffs that mean allergy versus tolerance differ by age, geography, and risk profile. A result that looks borderline in one published study may look high or low in another.
  • Recent peanut reaction: If you have just had a major peanut reaction, antibody levels can be in flux. Waiting at least 4 to 6 weeks before testing gives a more stable picture.

What to Do With an Unexpected Result

If your Ara h 2 IgE is clearly elevated and you have a history of peanut reactions, the diagnosis is essentially confirmed: strict avoidance and an epinephrine auto-injector should be in place. If the result is high but you have never knowingly reacted, an allergist visit is the right next step before either eating peanut or committing to avoidance. If the result is undetectable but you have had reactions to peanut-containing foods, consider that something else in the food (other tree nuts, sesame, or another allergen) may be the real trigger, and broader component or skin testing is warranted.

For borderline results, a basophil activation test or supervised oral food challenge with an allergist remains the most definitive next step. Skin prick testing and whole-peanut IgE are useful companion tests that, together with Ara h 2, build a clearer picture than any one test alone.

What Moves This Biomarker

Evidence-backed interventions that affect your Peanut (Ara h 2) IgE level

↓ Decrease
Peanut oral immunotherapy (gradually increasing peanut doses under supervision)
If you are doing peanut oral immunotherapy, your Ara h 2 IgE will typically fall over months as your immune system shifts away from a pure allergic response. In a randomized trial of 58 people with severe peanut allergy, oral immunotherapy decreased specific IgE to Ara h 2 (and the related Ara h 6) without triggering sensitization to cross-reactive foods. Sustained successful immunotherapy is consistently linked to lower peanut-specific IgE and blunted basophil reactivity.
MedicationStrong Evidence
↓ Decrease
Natural resolution over time in childhood
In some children, Ara h 2 IgE falls naturally over years without any active treatment, and this trajectory tracks with outgrowing peanut allergy. In a longitudinal study of 156 children, decreasing Ara h 2 IgE and increasing peanut-specific IgG over time were linked to natural resolution, with about one in three infant peanut allergies resolving by age 10. This is not something you can force, but it is something you can detect with serial testing.
LifestyleModerate Evidence
↓ Decrease
Omalizumab (anti-IgE biologic injection)
Omalizumab is an injectable medication that binds free IgE in the bloodstream and was approved for food allergy after a randomized trial showed it raised the threshold for reaction to peanut and other foods in 180 patients including children as young as 1. Total and peanut-specific IgE levels drop on treatment. It does not cure peanut allergy but reduces accidental reaction risk and is sometimes combined with oral immunotherapy.
MedicationModerate Evidence

Frequently Asked Questions

References

17 studies
  1. Keet C, Plesa M, Szelag D, Shreffler W, Wood R, Dunlop J, Peng R, Dantzer J, Hamilton R, Togias a, Pistiner MThe Journal of Allergy and Clinical Immunology2021
  2. Dang T, Tang M, Choo S, Licciardi P, Koplin J, Martin PE, Tan T, Gurrin L, Ponsonby a, Tey D, Robinson M, Dharmage S, Allen KThe Journal of Allergy and Clinical Immunology2012
  3. Hemmings O, Du Toit G, Radulovic S, Lack G, Santos AFThe Journal of Allergy and Clinical Immunology2020
  4. Kim HY, Han Y, Kim K, Lee JY, Kim MJ, Ahn K, Kim JAllergy, Asthma & Immunology Research2015
  5. Ebisawa M, Moverare R, Sato S, Maruyama N, Borres M, Komata TPediatric Allergy and Immunology2012